EP (Enteromorpha prolifera) polysaccharide-containing composite health care product for reducing blood fat and preparation method of composite health care product

Abstract

The invention provides an EP (Enteromorpha prolifera) polysaccharide-containing composite health care product for reducing blood fat. The health care product is in a form of capsules, tablets or granules. The health care product is prepared from the following raw materials in parts by weight: 50-70 parts of EP polysaccharide extracts, 10-15 parts of radix puerariae extracts, 5-10 parts of herba gynostemmatis pentaphylli extracts, 5-10 parts of fructus crataegi extracts and 10-15 parts of monacolin-R. The invention also provides a preparation method of the health care product. The method comprises the steps as follows: mixing of the raw materials in parts by weight, forming, drying, packaging and checking to obtain a finished product.

Description

technical field [0001] The invention belongs to the field of health care products, in particular to a compound enteromorpha polysaccharide-lowering blood lipid health care product and a preparation method thereof. Background technique [0002] Cardiovascular and cerebrovascular diseases are collectively referred to as cardiovascular and cerebrovascular diseases, and generally refer to diseases such as heart disease, cerebral thrombosis, and cerebral hemorrhage caused by hyperlipidemia, blood viscosity, atherosclerosis, and high blood pressure. The number of people who die from cardiovascular and cerebrovascular diseases is as high as 15 million every year in the world, ranking first among various causes of death. [0003] Hyperlipidemia is the culprit that induces repeated rises in blood pressure. The blood is thick and the blood flow is blocked. The blood can only pass through by squeezing the blood vessels by the force of the blood flow. The pressure on the blood vessels ...

AI Technical Summary

Problems solved by technology

Therefore, the conclusion given by the Fujian Provincial Center for Disease Control and Prevention is: according to the judgment criteria in the "Assessment Method for Auxiliary Blood Lipid Lowering Function" (National Food and Drug Administration Baohua [2012] No. 107), it is believed that this product does not have the effect of auxiliary blood lipid lowering

In addition, this product was also informed by the staff of the Shandong Provincial Center for Disease Control and Prevention that the substrates of rats and human bodies are quite different, and clinical practice should be responsible for the lives of patients. It is cold, lotus leaf and tea are cool, only hawthorn is warm, and the effect of hawthorn's warmness and coolness is very limited, making the compound enteromorpha polysaccharide obviously too cold, which greatly stimulates the digestive system of the subjects. , with obvious side effects, therefore, it cannot be used in normal human trials

In addition, in fact, even if the products that have auxiliary blood lipid-lowering effect through animal tests are often used in clinical trials, they often do not have the auxiliary blood-lipid-lowering effect. As a test subject, the subject actually only has short-term hyperlipidemia, and the blood lipid index is easy to drop, but for a natural person with diabetes or hyperlipidemia, it is long-term hyperlipidemia, and the blood lipid index is not so easy to drop

[0008] Table 1. Effects of existing compound Enteromorpha polysaccharide products on blood lipids in rats (mmol / L, n = 10)

Images